Investing.com - Mesoblast reported on Thursday second quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Mesoblast announced earnings per share of $-0.2 on revenue of $2.38M. Analysts polled by Investing.com anticipated EPS of $-0.2033 on revenue of $2.35M.
Mesoblast shares are down 18.13% from the beginning of the year and are trading at $3.930 , down-from-52-week-high.They are under-performing the Nasdaq which is down 13.88% from the start of the year.
Mesoblast follows other major Healthcare sector earnings this month
Mesoblast's report follows an earnings matched by Roche Holding ADR on Thursday, February 3, 2022, who reported EPS of $1.29 on revenue of $17.54B, compared to forecasts EPS of $1.29 on revenue of $17.1B.
Pfizer had beat expectations on Tuesday, February 8, 2022 with fourth quarter EPS of $1.08 on revenue of $23.84B, compared to forecast for EPS of $0.8742 on revenue of $24.16B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar